R. Aires

O6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trial

Deepak Joshi, G. Hirschfield, C. Bowlus, Kris V. Kowdley +88 more

2026O6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trial1 citations Open access

Semantic Scholar

R. Aires

Most-cited papers

Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.

Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil.

Overt and occult hepatitis B virus infection among treatment‐naïve HIV‐infected patients in Brazil

Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients

A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa‐2a (40kD)/ribavirin

New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society

O6 Efficacy and safety of volixibat, an IBAT Inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: Results of the VISTAS trial

ASSOCIATION BETWEEN THE IL28B rs12979860 POLYMORPHISM AND THERAPY RESPONSE IN PATIENTS INFECTED WITH GENOTYPE 1 OF HEPATITIS C VIRUS IN CENTRAL BRAZIL

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Microelimination of hepatitis C in dialysis units: results from the Brazilian Registry for the elimination of HCV

LBO-006 Efficacy and safety of volixibat, an IBAT inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: results of the VISTAS trial

Microeliminação da hepatite C em unidades de diálise: resultados do Registro Brasileiro para eliminação do HCV

1107 PREDICTIVE VALUE OF FIB-4 VS METAVIR ON SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: FINAL ANALYSIS FROM THE LARGE MULTINATIONAL PROPHESYS TRIAL

BASELINE CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF RIBAVIRIN > 800 MG/DAY AMONG G2/3 PATIENTS PRESCRIBED PEGINTERFERON ALFA-2A (40KD) FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS FROM PROPHESYS